Published on : Jul 21, 2016
ALBANY, New York, July 21, 2016: ResearchMoz.us has announced the addition of the “Ovarian Cancer-Pipeline Insights, 2016” report to its offering. This report provides a thorough evaluation of the market and encapsulates an evaluation of the therapeutic developments in the market for ovarian cancer. It also presents insights into the research and development activities as well as technologies utilized for the development of therapeutic products. Furthermore, the development stages of pipeline molecules and the inactive and discontinued projects in the pipeline have also been elaborated upon under this market study.
The report starts by presenting an overview on the market for ovarian cancer. In the overview section, the major symptoms and signs of ovarian cancer, its diagnosis, treatment, and the pipeline therapeutics utilized for the treatment have been presented. Ovarian cancer is the cancer of the ovaries and is the most common type of cancer amongst the female population globally. Epithelial tumors, germ cell tumors, and stromal tumors are the major types of ovarian cancers. A number of symptoms and signs are associated with this type of cancer. These include abdominal pressure, pelvic discomfort, swelling, urinary urgency, change in bladder habits, absence of energy, and lower back pain.
The diagnosis of this type of cancer takes place through ultrasound tests, blood, tests, pelvic examination, and other kinds of tests such as CT, PET, and MRI. The treatment of ovarian cancer depends on the stage in which this cancer is diagnosed. Based on the stage, biological therapy, radiation, chemotherapy, and surgery are amongst the prime treatment options utilized. Nowadays, the prime companies operating in the ovarian cancer market are focusing on producing targeted therapies for this type of cancer.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=745900
In the following section of the study, the pipeline therapeutics in the global ovarian cancer market have been presented. These include the early stage, mid stage, and last stage products in the global ovarian cancer market. As per the report, monoclonal antibodies such as Merck’s Avelumab, Morphotek’s Farletuzumab, and Roche’s Pertuzumab are in their phase III stage of development. The report further states that a number of big pharmaceutical companies with a number of preregistration products are also operating in the market for ovarian cancer. Paclitaxel by Oasmia Pharmaceutical AB and Cediranib by AstraZeneca are the major drugs that are still in the preregistration stage of development and will be launched shortly in the global ovarian cancer market.
Moving further, the major dynamics shaping the growth of this market have been highlighted. The increasing number of aging women and the growing occurrence of ovarian cancer globally are amongst the chief factors propelling the development of the global ovarian cancer market. In addition, the increasing number of pipeline drugs and therapies and the rising government funding will also provide impetus to the growth of this market. However, the introduction of generic drugs as well as the patent expiration of blockbuster drugs such as Paraplatin, Gemzar, Hycamtin, and Taxol may inhibit the growth of the global ovarian cancer market.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com